Evidence map›Paper›PMID 42719113›Full record

ReviewFrontiers in immunology2026

Advances in nanomaterial-based delivery systems for inducing transplantation tolerance.

Qingqing Li, Yun Zhang, Jinwei Wu, Dongxing Huang, Zhongquan Qi

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qingqing Li *Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Yun Zhang *Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Jinwei WuInfectious Disease Laboratory, Guangxi AIDs Clinical Treatment Center, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
Dongxing HuangFujian Duanneng Cell Technology Co., Ltd., Xiamen, Fujian, China.
Zhongquan QiGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organ transplantation is the primary therapeutic approach for patients with end-stage organ failure. However, challenges such as transplant rejection, the toxic side effects of long-term systemic immunosuppression, and substantial economic burdens remain pressing issues in clinical practice. The goal of inducing donor-specific transplantation tolerance is considered the most effective strategy to address these problems. Conventional tolerance-inducing strategies, including hematopoietic chimerism establishment, costimulatory signal blockade, and regulatory cell therapy, are often hampered by key limitations such as myeloablative toxicity, resistance from memory T cells, high costs associated with

Indexed as

Drug Delivery SystemsGraft RejectionNanostructuresOrgan TransplantationTransplantation ToleranceAnimalsHumansdelivery systemsimmune regulationnanomaterialsorgan transplantationtransplantation tolerance

Identifiers

PMID42719113
PMCPMC13555383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.